



MAYO CLINIC
LABORATORIES

CHRONIC LYMPHOCYtic LEUKEMIA

Testing for Prognosis
and Risk Stratification

Our chronic lymphocytic leukemia (CLL) testing provides important prognostic determination and assists physicians when determining the appropriate risk stratification to make informed treatment decisions for patients. This testing also meets all requirements of the National Comprehensive Cancer Network (NCCN) and CLL-International Prognostic Index (CLL-IPI) guidelines.

Methodology	Test ID	Test Name	Test Description	Acceptable Specimen
FISH	CLLF	Chronic Lymphocytic Leukemia (CLL), FISH	<p>Panels include testing for the following abnormalities using the probes listed:</p> <p>6q-, D6Z1/MYB 11q-, D11Z1/ATM</p>	Blood, Bone Marrow
	SLL	Small Lymphocytic Lymphoma, FISH	<p>+12, D12Z3/MDM2 13q-, D13S319/LAMP1 17p-, TP53/D17Z1 t(11;14), CCND1/IGH</p> <p>When an <i>IGH</i> rearrangement is identified, reflex testing will be performed to identify the translocation partner. Probes include identification of t(14;18)(q32;q21) IGH/BCL2 and t(14;19)(q32;q13) IGH/BCL3.</p>	Paraffin-Embedded Tissue (non-decalcified)
Molecular	BCLL	<i>IGH</i> Somatic Hypermutation Analysis, B-Cell Chronic Lymphocytic Leukemia (B-CLL)	Next-generation sequencing (NGS) technology represents a significant improvement over existing Sanger assays by allowing for batch sample analysis and simultaneous identification of clonal <i>IGH</i> rearrangement, the tumor-specific rearrangement sequence, and determination of somatic mutation percent.	Blood, Bone Marrow
	P53CA	Hematologic Neoplasms, <i>TP53</i> Somatic Mutation, DNA Sequencing Exons 4-9	Utilizing PCR and Sanger sequencing focused on exons 4-9 of the <i>TP53</i> gene, this testing encompasses more than 90% of described pathologic mutations and covers the coding exons of the critical DNA binding regions.	Blood*, Bone Marrow, Tissue
Flow Cytometry	CLLMV	CLL Monitoring Minimal Residual Disease (MRD) Detection	Confirming the presence or absence of minimal residual disease MRD in patients with known CLL who are either post-chemoimmunotherapy or post-bone marrow transplantation.	Blood, Bone Marrow

*Flow cytometry CKP53 protocol may be performed on peripheral blood samples to verify diagnosis of CLL and determine the percent B-cells in the sample prior to *TP53* testing

MAYO CLINIC LABORATORIES | 3050 Superior Drive NW | Rochester, MN 55901 | mayocliniclabs.com | 800-533-1710

©2019 Mayo Foundation for Medical Education and Research. All rights reserved. MAYO, MAYO CLINIC, Mayo Clinic Laboratories and the triple-shield Mayo logo are trademarks and service marks of MFMER.

MC2775-288